<DOC>
	<DOCNO>NCT00503568</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's tumor cell may help body build effective immune response kill non-small cell lung cancer cell . PURPOSE : This phase I trial study effect gp96-Ig vaccine therapy treat patient stage III , stage IV , relapse non-small cell lung cancer treat first-line chemotherapy .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III , Stage IV , Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy</brief_title>
	<detailed_description>Overall Goals : - evaluate safety induction anti-tumor immunity administration immunogenic human tumor cell vaccine , assess immune response relation clinical outcome . Primary Aim : - evaluate safety administer heat shock protein gp96-Ig-secreting allogeneic tumor cell-vaccine ( gp96-Ig vaccine ) patient advanced NSCLC . Secondary Aims : - study immune response vaccination , - monitor clinical response - recommend dose-schedule combination test initial Phase II trial vaccine efficacy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm NSCLC ( squamous , adeno , large cell anaplastic , bronchoalveolar , nonsmall cell carcinoma NOS ) : stage IIIB malignant pleural effusion , stage IV , recurrent disease . At least one site bidimensionally measurable disease . Metastasis present treat must stable CT scan MRI least 8 week . Patient must receive fail least one line chemotherapy . Age &gt; = 18 year . ECOG performance status 02 . Life expectancy &gt; = 3 month . Laboratory parameter : Hemoglobin level &gt; = 10.0 ( transfusion allow necessary ) . ANC &gt; = 1,500 . Platelets &gt; = 100k . Creatinine clearance &gt; = 50 ml/min . Total direct bilirubin : &lt; 2.5 X upper institution limit normal . Liver function test : AST , ALT , AlkP &lt; 2.5 X upper institution limit normal . Signed informed consent . Autopsy consent although requirement study entry , patient consent participate study make aware critical importance postmortem examination event patient 's death receiving therapy experimental vaccine . Therefore , pretreatment write agreement autopsy seek patient , verbal agreement autopsy seek presence next kin family member . Exclusion Criteria Active symptomatic cardiac disease congestive heart failure , angina pectoris recent myocardial infarction . Patients history condition stable take cardiac medication also exclude . Pregnant lactate woman ( negative test pregnancy require woman childbearing potential ) . Known HIV infection . Uncontrolled untreated brain spinal cord metastasis . Active infection . Concomitant steroid immunosuppressive therapy . Other active malignancy present within past three year , except basal and/or squamous cell carcinoma ( ) situ cervical cancer . Alcohol chemical abuse . Meningeal carcinomatosis . Chemotherapy , radiation therapy , antitumor therapy last four week . Prior biologic response modifier therapy . Refusal fertile men woman use effective birth control measure six month completion treatment study . Immune deficiency syndrome , include follow : rheumatoid arthritis , systemic lupus erythematosus , Sjogren 's disease , sarcoidosis , vasculitis , polymyositis , glomerulonephritis . Compromised lung function : FeV1 &lt; 30 % predict value , DLCO &lt; 30 % predict value , PCO2 &gt; 45 mmHg . Any patient enrol study whose respiratory symptom experience marked deterioration relate know cause , pneumonia , congestive heart failure , pulmonary embolism , repeat PFT evaluation , parameter value FeV1 , DLCO , PCO2 see , exclude treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>